Paper Details

  1. Home
  2. Paper Details

Hyperbaric oxygen exposure alleviate metabolic side-effects of olanzapine treatment and is associated with Langerhans islet proliferation in rats.

Author: Al-AzaizehRasha, Al-RusanOmar M, AlQudahMohammad, HaddadHusam K, KhalifehMohammad, MasaadehAmr

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled Trial, VeterinaryRandomized controlled trials involving animals. They evaluate the efficacy and safety of treatment methods.

Overview

Olanzapine, a second-generation antipsychotic drug, is associated with metabolic side effects. This study investigated the potential of hyperbaric oxygen therapy (HBOT) to mitigate these effects in rats. HBOT reversed olanzapine-induced increases in fasting blood sugar, insulin resistance, and amylase levels, while improving serum insulin, triglyceride, and HDL cholesterol levels. HBOT also increased the number of pancreatic Langerhans islets. These findings suggest that HBOT could be an alternative approach to controlling metabolic disorders associated with olanzapine treatment.
Paper Details　
Original Abstract of the Article :
<b>Introduction:</b> Olanzapine (OLZ) is one of the second-generation antipsychotics drugs (APDs) used to treat several psychiatric illnesses. Olanzapine treatment is often associated with many metabolic side effects in a dose dependent manner such as obesity, dyslipidemia and insulin resistance, i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801520/

データ提供：米国国立医学図書館（NLM）

Hyperbaric Oxygen Therapy: A Potential Solution for Olanzapine-Induced Metabolic Side Effects

[Olanzapine (OLZ)] is a widely used [antipsychotic medication], but its use is often associated with [metabolic side effects] such as [obesity, dyslipidemia, insulin resistance, and type II diabetes]. This study investigates the potential of [hyperbaric oxygen therapy (HBOT)] to mitigate these metabolic side effects in rats. The researchers divided 36 rats into four groups: [OLZ-treated rats with HBOT, OLZ-treated rats without HBOT, control rats with HBOT, and control rats without HBOT]. Their findings revealed that [HBOT effectively reversed the metabolic side effects] induced by olanzapine treatment. Moreover, [HBOT was associated with an increase in Langerhans islet proliferation], suggesting a potential positive impact on [pancreatic function].

Hyperbaric Oxygen Therapy: A Promising Approach for Metabolic Disorders

The study suggests that hyperbaric oxygen therapy may offer a viable approach to mitigate metabolic side effects associated with olanzapine treatment. It’s like finding a hidden spring in the desert that provides both hydration and healing properties. The research underscores the potential of HBOT as a therapeutic tool for metabolic disorders.

The Potential of Hyperbaric Oxygen Therapy

The study highlights the potential of HBOT as a therapeutic approach to managing olanzapine-induced metabolic side effects. It’s like discovering a new oasis in the desert, offering a source of relief and rejuvenation for individuals seeking solutions to their health concerns. The research suggests that HBOT may hold promise as a therapeutic strategy for metabolic disorders.

Dr. Camel's Conclusion

This study presents promising evidence that hyperbaric oxygen therapy can effectively mitigate the metabolic side effects associated with olanzapine treatment. It’s like finding a hidden oasis in the desert: a source of relief and rejuvenation for individuals seeking solutions to their health concerns. The research underscores the potential of HBOT as a therapeutic tool for metabolic disorders and suggests further investigation to explore its clinical applications.

Date :
  1. Date Completed 2023-01-04
  2. Date Revised 2023-01-04
Further Info :

Pubmed ID

36590387

DOI: Digital Object Identifier

PMC9801520

Related Literature

Article Analysis
・Side Effects of olanzapine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.